| Why in the news? | Uganda Launches Groundbreaking Ebola Vaccine Trial |
| Vaccine Target | Sudan species of the Ebola virus |
| Trial Location | Uganda |
| Leading Institutions | Makerere University, Uganda Virus Research Institute (UVRI) |
| Supporting Organizations | WHO, CEPI, IDRC (Canada), EU HERA, Africa CDC |
| Vaccine Type | Recombinant vesicular stomatitis virus (rVSV) vaccine |
| Vaccine Donor | IAVI (non-profit organization) |
| Ethical Standards | Adheres to national and international regulations |
| Expected Timeline | Data collection within months |
| Global Impact | Potential for regulatory approval and improved outbreak control strategies |
| Discovery Year (Ebola) | 1976 |
| Virus Type | Orthoebolaviruses (formerly ebolavirus) |
| Location of Discovery | Democratic Republic of the Congo (DRC) |
| Virus Hosts | Fruit bats, primates (gorillas, monkeys, chimpanzees), forest animals (e.g., antelope) |
| Transmission | Zoonotic (from animals to humans via body fluids) and human-to-human (via contact with body fluids) |
| Symptoms | Fever, diarrhea, vomiting, bleeding, death (average case fatality rate: 50%) |
| Treatment | No known cure; FDA-approved monoclonal antibodies (Inmazeb, Ebanga) for Ebola Zaire strain; supportive care (fluids, blood/plasma) |
| Incubation Period | 2 to 21 days |
| Recovery Factors | Virus exposure, early treatment, immune response, age |
| Fatality Rate | Around 50% |
